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Abstract
Background: Early diagnosis and prompt effective therapy are crucial for the prevention of tuberculosis (TB)
transmission, particularly in regions with high levels of multi-drug resistant TB. This study aimed to evaluate the extent
of delay in diagnosis and treatment of TB in Uzbekistan and identify associated risk factors.
Methods: A cross-sectional study was performed on hospital patients with newly diagnosed TB. The time between the
onset of respiratory symptoms and initiation of anti-TB treatment was assessed and delays were divided into patient,
health system and total delays. Univariable and multivariable logistic regression analysis was used to evaluate
determinants of diagnostic and treatment delay.
Results: Among 538 patients enrolled, the median delay from onset of symptoms until treatment with anti-TB drugs
was 50 days. Analysis of the factors affecting health-seeking behaviour and timely treatment showed the presence of
the patient factor. Self-medication was the first health-seeking action for 231 (43%) patients and proved to be a
significant predictor of delay (p = 0.005), as well as coughing (p = 0.009), loss of weight (p = 0.001), and visiting private
and primary healthcare facilities (p = 0.03 and p = 0.02, respectively).
Conclusion: TB diagnostic and treatment delay was mainly contributed to by patient delay and should be
reduced through increasing public awareness of TB symptoms and improving public health-seeking behaviour for
timely initiation of anti-TB treatment. Efforts should be made to minimise irrational use of antibiotics and support
interventions to restrict over-the-counter availability of antibiotics.
Background
Tuberculosis (TB) is one of the oldest human diseases,
yet it still cannot be defeated and remains second only
to HIV as a leading cause of death from infectious dis-
eases worldwide. In 2012, there were an estimated 8.6
million new TB cases and 1.3 million deaths [1]. The
TB epidemic has been fuelled by a surge in HIV–TB
co-infection and compounded by the growing emergence
of multi- and extensively drug resistant (M/XDR) TB
strains, with a high prevalence in the former Soviet Union
countries, especially in Central Asia [2,3]. Uzbekistan is
one of the four Central Asian states among the 27 identi-
fied by the World Health Organization (WHO) with the
highest burden of multi-drug resistant TB (MDR-TB).
The highest MDR-TB incidence rate exists in North-
western Karakalpakstan, where the immunity of the
population has been undermined by the Aral Sea eco-
logical catastrophe. Also cotton growing regions suffer
particularly because the immunity of the local people
has been adversely affected by unlimited application of
pesticides [4].
Substantial gains have been made in reducing TB
morbidity and mortality in the past decade. New direc-
tives have been approved, TB control programmes have
been implemented to prevent transmission in the commu-
nity, and a good-quality directly observed therapy short-
course strategy (DOTS) has been expanded throughout
the country with 100% regional coverage [5].
However, the current positive trend is insufficient to
ensure stable and efficient control of TB. The TB sur-
veillance and monitoring report in Europe and Central
Asia yielded an estimated 14,787 incident cases of TB in
Uzbekistan in 2012 [3]. There were an estimated 2,400
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(23%) new and 1,600 (62%) retreatment MDR-TB cases
among notified TB patients [6]. In 2012, 1,728 MDR-
TB cases were detected among patients with reported
TB [6]. This is 43.2% of all estimated cases, indicating a
low detection rate of MDR-TB. Given the substantial
incidence of MDR-TB in Uzbekistan, delay in diagnosis
increases the risk of onward transmission through un-
treated patients leading to aggravation of the situation
in the region.
Delay in TB diagnosis and treatment has been studied
internationally and several definitions of delay have
been used, but frequently applied definitions are delay
due to the patient or healthcare system. To the best of
our knowledge, the possible delays in diagnosis and ini-
tiation of anti-TB treatment have not been extensively
researched in Central Asia, and there are limited data
from the high MDR-TB-endemic countries of the former
Soviet Union.
This article reviews the extent of delay in diagnosis
and treatment of TB and associated risk factors that
might be tackled to promote early diagnosis and im-
prove TB prevention.
Methods
Setting and study design
Between August 2013 and January 2014, we conducted
a cross-sectional study among newly diagnosed pul-
monary TB patients in two cities of Uzbekistan,
Tashkent and Nukus. In Tashkent, the study was con-
ducted at the Republican Specialized Scientific and
Practical Medical Centre for Phthisiology and Pulmo-
nology providing treatment to patients from across
the country. In Nukus, the main city of the Autono-
mous Republic of Karakalpakstan, two hospitals and
one dispensary were chosen as study settings.
Study population
We reviewed the TB Electronic Surveillance Case-based
Management System (ESCM) database of all cases of
culture-confirmed pulmonary TB registered in the se-
lected facilities from August 2013 to January 2014.
Paper-based inpatient and outpatient medical cards
from adult patients (aged ≥15 years) were reviewed and
all patients with newly diagnosed pulmonary TB were
included in the study. We excluded those with recur-
rent TB.
The patients were interviewed using an adapted and
slightly modified version of the WHO questionnaire de-
veloped for the assessment of TB diagnostic and treat-
ment delay [7]. The questionnaire was pre-tested and
administered by trained doctors and health workers. All
interviews were performed in the Uzbek, Karakalpak or
Russian language.
Verbally informed consent was obtained from patients
prior to inclusion in the survey, and the study was ap-
proved by the Ethical Committee of Charles University
in Prague, the Ministry of Health of the Republic of
Karakalpakstan, and the Ethical Committee of the
Republican Specialized Scientific and Practical Medical
Centre for Phthisiology and Pulmonology.
Definitions
Patients were considered to have pulmonary TB on the
basis of clinical, pathological and radiological findings
confirmed bacteriologically and histologically. The time
between onset of respiratory symptoms and initiation of
anti-TB treatment was assessed and delays were divided
into three types. Patient delay was measured in days
from the first onset of any TB symptom (e.g., cough,
fever, weight loss, or night sweats) until the first presen-
tation to the healthcare system (not necessarily a TB fa-
cility). Patient delays were allowed to be negative,
indicating the situation in which regular healthcare visits
detected TB infection before onset of symptoms. Health-
care delay was measured as the number of days from
first presentation to the healthcare system until the start
of TB treatment. Total delay was calculated as patient
delay plus healthcare delay (and thus may also take
negative values). Comorbidity was defined as underlying
cardiovascular, gastrointestinal, pulmonary, immunologic
or malignant disease. Self-medication was defined as use
of any medication not prescribed by a healthcare profes-
sional. Antibiotics and other medications are available at
pharmacies in Uzbekistan over-the-counter and without
a prescription.
Laboratory techniques
Analysis of sputum samples for smear microscopy, cul-
ture, drug-susceptibility testing (DST) and real-time
PCR (Xpert MTB system) were conducted as per inter-
national guidelines [8-10] at the National Reference
laboratory in Tashkent and at the Mycobacterial La-
boratory in Nukus. Preliminary confirmation of acid-
fast bacilli (AFBs) was performed using Ziehl–Neelsen
staining while culturing was done using Lowenstein–
Jensen medium. AFB strains were classified according
to the WHO/International Union against Tuberculosis
and Lung Disease scale: 1+ (10–99 AFBs per 100 fields),
2+ (1–10 AFBs per individual field), 3+ (10–100 AFBs
per individual field), and 4+ (>100 AFBs per individual
field) [11]. The BACTEC MGIT 960 system, based on
the critical concentration method, was used for deter-
mining susceptibility to first-line drugs. DST for second
line drugs was performed using the agar proportion
method in Lowenstein–Jensen medium. Provider-initiated
HIV testing is routinely recommended for all patients pre-
senting with symptoms and signs of TB and TB diagnosed
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patients [12,13]. MDR-TB and HIV-associated TB sputum
samples were analysed using real-time PCR Xpert MTB
assay.
Data collection and analysis
The questionnaire included sociodemographic charac-
teristics, risk factors of TB, comorbidity, and TB know-
ledge and attitudes. Follow-up data included history of
TB treatment, such as a detailed description of diagnos-
tic investigation process, first symptoms perceived by
the patient, and health seeking actions. The patients
were also asked to complete a number of questions
measuring psychosocial aspects, for example, feeling
ashamed about having TB, fear of social isolation and
stigma. In addition, patient medical cards were reviewed
for TB diagnostic information, such as date of diagnosis,
date of treatment initiation, and laboratory results.
Univariable and multivariable logistic regression ana-
lysis was used to evaluate risk factors for patient, health-
care and total delays, which were dichotomised into
delay versus non-delay. Following studies in comparable
countries (e.g. Rabin et al. [14]), median delays were
used as a cut-off. Variables included in the multivariable
model were chosen according to the strategy of purpose-
ful selection [15] based on behavioural and biological
plausibility as well as statistical (p ≤ 0.2) criteria. The re-
gression outcome was given by the estimated (adjusted)
odds ratios and the corresponding 95% confidence inter-
vals. Hypothesis tests for regression coefficients (Wald
tests) were performed and expressed with p values at the
significance level α = 0.05. PASW statistical software was
used for all analyses (IBM Corporation, Armonk, NY,
USA, version 18.0).
Knowledge and stigma were measured using scoring
systems. For stigma, the responses to the corresponding
questions were marked on a five-point scale (1, strongly
agree; 2, agree; 3, no opinion; 4, disagree; and 5, strongly
disagree), with a low score corresponding to a high de-
gree of stigma (except for the question “Do you feel you
can talk to others about your TB” where the score was
first reversed before addition to its domain). The mean
percentage score for stigma was calculated as 100 times
the sum of scores obtained divided by the maximum
scores that could be obtained. This resulted in a Cron-
bach α value of 0.655 in cases for which all 10 stigma
questions were answered (unmarried/single patients)
and 0.621 in cases for which the last stigma question
was unanswered. Knowledge was computed in a less
straightforward way to reflect the different degrees of
difficulty for the individual questions. For questions
about knowledge, contagiosity and curability of TB, the
wrong answer resulted in a score of 0 and the right an-
swer in a score of 1, except for the question of whether
TB is contagious, which received a score of 2. The right
answer to the question about the means of transmission
resulted in a score of 3, and all other answers resulted in
a score of 1. For the question about common symptoms
of pulmonary TB, the score was defined as the number
of marked symptoms divided by six (the total number of
displayed symptoms). This gave a Cronbach α value of
0.545 for the five knowledge-related items.
Results
Baseline patient characteristics
We assessed 600 newly diagnosed pulmonary TB cases
that were confirmed bacteriologically. Fifty of these
showed TB recurrence, and 12 patients refused to par-
ticipate due to poor clinical conditions. The final sam-
ple comprised 538 patients, 243 from Karakalpakstan,
179 from Tashkent, and 116 representing all 12 prov-
inces of Uzbekistan. The characteristics of these pa-
tients are summarised in Table 1. The mean age was
40 years and there was no significant gender difference
in notified TB cases. The number of cases was, how-
ever, slightly higher in men than in women. The preva-
lence rate was highest in men aged 25–35 years. Of the
538 patients, 231 (42.9%) practiced self-medication or
consulted pharmacists with the onset of respiratory
symptoms and 124 patients (54.0%) self-treated with
antibiotics. The proportion of MDR-TB among new TB
cases was 41% and occurred predominantly in Karakal-
pakstan. No cases of XDR-TB were observed among
our patients.
Patient delay
The median patient delay for all patients included in the
study was 27 days [interquartile range (IQR), 6–62 days].
Delay was significantly longer in patients who abused al-
cohol, were HIV positive, and had specific TB symptoms
of persistent cough and loss of weight (Table 2). Addition-
ally, patients with positive sputum smear results and those
who self-medicated, ordinarily with antibiotics, had longer
diagnostic delay. The first healthcare provider consulted
(pharmacies, private or district outpatient clinics, ambu-
lance services) and time to reach the nearest health care
facility or facility providing TB treatment were signifi-
cantly associated with longer delay.
Health system delay
The median health system delay of 7 days (IQR, 1–32
days) seemed to be insignificant (Table 2). The health sys-
tem delay was associated with younger age, unemploy-
ment, or labour migration, for those who had recently
worked abroad (p = 0.001 and p = 0.02, respectively). Being
a health care worker was a strong risk factor (p = 0.01) for
health system delay, but could not be fully assessed since
there were only eight (1.5%) healthcare workers and all of
them had delayed diagnosis. Furthermore, patients who
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had longer health system delay also were HIV-positive,
stigmatised by TB disease, and prescribed antimicrobials.
Total delay
The median total delay was nearly 2 months (50 days,
IQR, 22–92 days), and 228 of 538 patients (42%) expe-
rienced a delay of ≥3 months. Patients with a cough,
loss of weight, who self-medicated, were prescribed
anti-TB medications by non-TB physicians, from dis-
tant location to healthcare facility, or facility providing
TB treatment experienced longer delays in the diagno-
sis and treatment of TB.
Further multivariate analysis revealed that self-
medication and initial consultation with a private fa-
cility predicted long patient delay, while administra-
tion of antimicrobial therapy as well as seeking care at
private clinics were risk factors for health system delay
(Table 3). Cough, self-medication, and private and pri-
mary healthcare facilities were associated with long
total delay.
Untreated MDR-TB is highly contagious; therefore, we
defined the extent of delay and evaluated risk factors
among patients with and without MDR-TB. Among
MDR-TB patients, there was a slightly longer median pa-
tient delay of 36 days, healthcare delay was 8 days, and
total delay was 47 days. There were no differences
Table 1 Characteristics of pulmonary tuberculosis patients





N (%) N (%)
Gender
Male 124 51.0 174 59.0
Female 119 49.0 121 41.0
M/F ratio 1.04 1.44
Age (years)
≤ 15-35 120 49.4 106 35.9
> 35 123 50.6 189 64.1
Education
Illiterate 13 5.3 9 3.1
Primary-Secondary 206 84.8 237 80.3
University/higher 24 9.9 49 16.6
Occupation
Employed 50 20.6 80 27.1
Healthcare worker 5 2.1 3 1.0
Unemployed 124 51.0 122 41.4
Student 7 2.9 9 3.1
Housewife 10 4.1 42 14.2
Retired 47 19.3 39 13.2
Labour migrant 27 11.1 27 9.2
Residence
Urban 132 54.3 225 76.3
Suburban 12 5.0 41 13.9
Rural 99 40.7 29 9.8
Smoking
Never 171 70.4 145 49.2
Current - - 24 8.1
Ex-smoking 72 29.6 126 42.7
Alcohol use
Never 163 67.1 165 55.9
Past history 69 28.4 84 28.5
Moderate/Excessive 11 4.5 46 15.6
Injection drug use
Yes 1 0.4 20 6.8
No 242 99.6 275 93.2
Comorbidities
Diabetes mellitus 12 4.9 40 13.6
HIV positive - - 32 10.8
COPD/emphysema/bronchitis 42 17.3 27 9.1
Symptoms
Cough 226 93.0 253 85.8
Fever 123 50.6 131 44.4
Loss of weight 191 78.6 191 64.7
Table 1 Characteristics of pulmonary tuberculosis patients
in Uzbekistan, 2014 (n = 538) (Continued)
Sputum smear-for acid-fast bacilli
Positive 117 48.1 166 56.3
Negative 126 51.9 129 43.7
Health facility first consulted
Pharmacy 131 53.9 100 33.9
Private clinic 4 1.6 23 7.8
Primary health center/polyclinic 42 17.3 91 30.8
TB facility 52 21.4 48 16.3
Traditional remedy 2 0.8 2 0.7
Ambulance 7 2.9 9 3.1
Other (AIDS Centre, Public hospital) 5 2.1 22 7.4
Treatment before TB diagnosis
Self-medicated 131 53.9 100 33.9
- Self-medicated with antibiotics 90 69.0 34 34.0
Prescribed antibiotics 55 22.6 114 38.6
Time taken to reach a TB health facility
<1/2 hour 108 44.4 46 15.6
1/2-1 hour 58 23.9 111 37.6
≥ 1 hour 77 31.7 138 46.8
TB = tuberculosis, MDR-TB =multidrug-resistant tuberculosis, HIV = human
immunodeficiency virus, COPD = chronic obstructive pulmonary disease,
AIDS = acquired immune deficiency syndrome.
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Table 2 Risk factors for three delay stages of pulmonary tuberculosis patients in Uzbekistan, 2014 (n = 538)






Median P value Median P value Median P value
Gender
Male 298 30 0.08 6.5 0.56 49 0.8
Female 240 23.5 1 8 1 50.5 1
Age (years)
≤ 15-35 226 25 0.3 5 0.01* 48 0.1
> 35 312 28 0.4 9 0.1 50 0.4
Education
Illiterate 22 31 1 3 1 38.5 1
Primary-Secondary 443 25 0.5 7 0.2 50 0.6
University/higher 73 30 0.9 9 0.1 49 0.7
Occupation
Employed 130 21 1 10 1 57 1
Healthcare worker 8 23 0.4 4 0.01* 27.5 0.8
Unemployed 246 30 0.2 5 0.001* 48 0.3
Student 16 17 0.2 14.5 0.9 36.5 0.4
Housewife 52 25 0.8 9 0.3 50 0.8
Retired 86 28 0.3 9 0.2 54 0.6
Labour migrant 54 34 0.9 7 0.02* 60.5 0.5
Residence
Urban 357 25 1 7 1 49 1
Suburban 53 25 0.8 18 0.01* 56 0.2
Rural 128 30 0.1 4 0.1 50.5 0.9
Smoking
Never 316 25 1 6 1 50 1
Current 24 42 0.2 8 0.2 48.5 0.9
Ex-smoking 198 29 0.3 8 0.2 49.5 0.7
Alcohol use
Never 328 24 1 6 1 47 1
Past history 153 34 0.03* 7 0.1 54 0.1
Moderate/Excessive 57 21 0.03* 10 0.1 50 0.1
Injection drug use
Yes 21 24 0.5 11 0.3 48 0.9
No 517 27 1 7 1 50 1
Comorbidities
Diabetes mellitus 52 23 0.9 10 0.6 51.5 0.9
HIV positive 32 14.5 0.03* 19.5 0.02* 46.5 0.6
COPD 69 31 0.5 4 0.9 46 0.2
Symptoms
Cough 479 29 0.008* 7 0.4 53 0.0001
Fever 254 29 0.3 7 0.8 53 0.2
Loss of weight 382 35 0.0001* 7 0.7 57 0.0001
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between the two groups for predictors of diagnostic
delay. However, high social stigma prevailed in patients
with MDR-TB (odds ratio 1.39, 95% confidence interval
0.74–2.62).
Discussion
We found that the median total delay time from onset
of symptoms until diagnosis and initiation of anti-TB
treatment was 50 days and was mainly contributed to by
patient delay of 27 days. The healthcare system delay of
7 days was significantly shorter than patient delay. These
data are similar to the results of recent studies from
Georgia and Ukraine [14,16].
Importantly, in our study, 79 of 228 cases with >2 months
total delay had MDR-TB, for which early and accurate
diagnosis is critical to timely initiation of effective
treatment.
The main factors associated with total delay in a co-
hort of TB patients after adjusted multivariate analysis
were self-medication, seeking initial care from a primary
health facility or the private sector, and cough.
Almost half of the patients used unprescribed antimi-
crobials before diagnosis and treatment of TB. It is
known that self-medication with antibiotics can delay
and mask the correct diagnosis of infectious disease [17].
Several studies have reported that antibiotic exposure, in
Table 2 Risk factors for three delay stages of pulmonary tuberculosis patients in Uzbekistan, 2014 (n = 538) (Continued)
Sputum smear-for acid-fast bacilli
Positive 283 31 0.008* 8 0.3 54 0.006*
Negative 255 21 1 6 1 44 1
Health facility first consulted
Pharmacy 231 41 0.0001* 6 0.0001* 56 0.0001*
Private clinic 27 14 0.02* 36 0.004* 88 0.01*
Primary health center/polyclinic 133 12 0.0001* 16 0.0001* 41 0.004*
TB facility 100 25 1 3 1 33.5 1
Traditional remedy 4 14 0.1 5 0.4 28 0.03
Ambulance 16 16 0.006* 5.5 0.4 25.5 0.05
Other (AIDS Centre, Public hospital) 27 30 0.6 6 0.4 45 0.2
Treatment before TB diagnosis
Self-medicated 231 41 1 6 1 56 1
Self-medicated with antibiotics 124 54.5 0.0001* 4 0.03* 62.5 0.0001*
Prescribed antibiotics 169 15 0.09 25 0.0001* 58 0.02*
Time taken to reach a TB health facility
<1/2 hour 154 24 0.5 6 0.2 39 0.3
1/2-1 hour 169 26 0.4 8 0.4 55 0.4
≥ 1 hour 215 29 0.04* 7 0.6 51 0.04*
HIV = human immunodeficiency virus, COPD = chronic obstructive pulmonary disease, AIDS = acquired immune deficiency syndrome. * p <0.05.
Table 3 Multiple logistic regression analysis of risk factors for three delay stages of pulmonary tuberculosis patients in
Uzbekistan, 2014 (n = 538)
Predictors Patient delay; OR (95%CI) Health system delay; OR (95%CI) Total delay; OR (95%CI)
Cough 0.72 (0.38 to 1.39) 1.02 (0.53 to 1.96) 4.67 (1.23 to 17.1)*
Loss of weight 0.25 (0.16 to 0.4)* 1.04 (0.65 to 1.67) 0.42 (0.27 to 0.65)*
Sputum positive 0.60 (0.40 to 0.89)* 1.12 (0.73 to 1.69) 0.77 (0.52 to 1.13)
Self-medication 1.53 (1.01 to 2.33)* 0.91 (0.53 to 1.53) 1.58 (1.12 to 2.23)*
Self-medication with antibiotics 0.73 (0.40 to 1.31) 1.31 (0.69 to 2.45) 0.94 (0.53 to 1.68)
Prescribed antibiotics N/A 2.19 (1.18 to 4.09)* 0.5 (0.31 to 0.81)
Primary health center/ Polyclinic 1.68 (0.49 to 5.63) 3.09 (0.61 to 15.74) 5.53 (1.29 to 23.72)*
Private clinic 2.96 (1.49 to 5.88)* 2.87 (1.83 to 4.54)* 4.67 (1.27 to 17.11)*
OR = odds ratio, CI = confidence interval, N/A = not applicable.
*p <0.05.
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particular fluoroquinolones, can delay the diagnosis of TB
and initiation of anti-TB treatment [18-20]. However, in
our study, the contribution of the class of antibiotics was
not investigated.
In addition, both first- and second-line anti-TB drugs
are available without prescription, which encourages
self-treatment and the uncontrolled use of these drugs
may contribute to higher levels of resistance, with a con-
sequent deleterious impact on treatment success [21,22].
Self-treatment only temporarily relieved the symptoms
and resulted in exhaustion, weakness and the need for
transportation by ambulance.
Importantly, care seeking from a primary health centre/
polyclinic was associated with a delay in diagnosis that
might have been due to failure to comply with recom-
mended diagnostic standards. Patients managed in primary
health centres were repeatedly treated with antibiotics (in-
cluding fluoroquinolones) for upper respiratory infection
or presumed community-acquired pneumonia. Prolonged
delay in diagnosis ranging from 1 to 12 months was seen
in 8% of patients first approaching public polyclinics. In-
adequate case detection at primary health care contributes
to low treatment success rate and an extended period of
disease transmission, particularly MDR-TB. Of particular
concern were private physicians who were most often
consulted first by patients living in distant places. As in
some studies from developing countries [23,24], private
physicians tend to deviate from recommended TB man-
agement guidelines and rely on chest radiography rather
than referral of patients for sputum microscopy or moni-
toring treatment [25].
HIV infection was significantly associated with longer
patient and health system delay. This was possibly because
symptoms were less specific and might have been consid-
ered by the patients to be associated with HIV. Despite all
HIV-infected patients being routinely screened for latent
and active TB infection, the interpretation of test results
might be complicated by a higher incidence of false-
positive results (e.g., negative tuberculin skin test, negative
sputum and normal chest x-ray findings), and lack of spe-
cificity of symptoms [26].
The reason that cough was associated with delayed TB
diagnosis is not clear. It might be that patients consid-
ered it as a transient symptom from an upper respiratory
illness, hence initiating self-treatment lasting until de-
terioration and manifestation of other specific symp-
toms. Furthermore, timely referral to healthcare facilities
was challenging for work migrants due to limited access
to health care, financial constraints, poor health literacy,
and fear of deportation after positive TB diagnosis.
Although awareness and knowledge of TB were high
in Karakalpakstan, the extent of total delay was similar
across regions, yet patient delay was longer in Karakal-
pakstan, possibly due to greater stigmatisation, fear and
belief in the incurability of the disease. Approximately
30% of those with diagnostic delay in Karakalpakstan
had relatives and friends with MDR-TB or even experi-
enced the death of a family member, and the feeling of
hopelessness was overpowering. This is in line with the
findings of Kuznetsov et al. [27], who described hope-
lessness as a basis for TB diagnostic delay in the
Arkhangelsk region.
In agreement with previous studies on delay in TB
diagnosis [28,29], we found that current smoking was as-
sociated with longer patient delay. This could be ex-
plained by the fact that some TB symptoms can be
confused with other smoking-related conditions [30].
For example, chronic obstructive disease was found to
be a comorbid condition in 14% of smokers diagnosed
with TB and could mask the symptoms of TB, resulting
in delayed TB diagnosis. Alcohol abuse was another risk
factor for delayed TB diagnosis.
There were several limitations to our study. First, re-
call bias may have influenced our results, because the
onset of first symptoms may have been inaccurately re-
ported by the patients. In order to minimise patient re-
call bias, we encouraged physicians to check patient
medical cards when completing the questionnaire. Sec-
ond, a lack of information on the class of antibiotic used
for self-medication, as well as that prescribed by the
physician, meant that fluoroquinolone use may have
been associated with delay in diagnosis of TB.
Although we investigated the risk factors associated
with delayed diagnosis and treatment of TB, there are
clinical consequences of late TB diagnosis. Further stud-
ies are required to assess morbidity, mortality, treatment
success, outcome of previous antibiotic treatment, risk
of transmission, and development of active TB associ-
ated with delay in initiation of treatment.
However, the significance of delay for treatment suc-
cess remains unclear.
Conclusion
TB diagnostic and treatment delay should be reduced to
the least possible time interval. There is a need to de-
crease TB stigma and promote public awareness of TB
curability and the importance of early referral to health
services. An essential step is to improve the diagnostic
awareness among private and primary care practitioners.
A high index of suspicion of TB should be maintained in
public and private practitioners and an appropriate diag-
nostic work-up should be performed. Regulations prohi-
biting the dispensing of antibiotics, including anti-TB
medicines, without prescription should be enforced to
prevent further development of drug- resistance.
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